A clinical distinction that matters Diphtheria antitoxin (DAT) remains an important component of treatment for respiratory diphtheria. Yet one distinction is easy to lose during an outbreak: DAT neutralises circulating diphtheria toxin; it does not reverse cellular injury that has already occurred. This matters when patients present late with myocarditis, neurological complications, renal dysfunction or respiratory compromise. My experience as a sub-national case management lead during diphtheria outbreak response in Nigeria reinforced how differently patients can present. Some arrive early, while others reach care after substantial toxin-mediated injury has developed. Complications should prompt more intensive clinical management—not the assumption that DAT has become irrelevant. What DAT can—and cannot—do Diphtheria toxin interferes with cellular protein synthesis and can cause multisystem injury. DAT binds and neutralises circulating toxin before it becomes irreversibly associated with tissues. Its potential benefit is therefore greatest when given early. Importantly, established organ injury does not, by itself, mean that DAT should be withheld when there is a clinical indication for antitoxin. Rather, expectations about its role must be realistic. DAT is not a treatment for renal failure, myocarditis or neurological injury. A patient with renal dysfunction may require fluid and electrolyte management and renal replacement therapy when indicated; a patient with myocarditis may require cardiac monitoring and haemodynamic support; and neurological complications may require airway protection, swallowing assessment and close respiratory monitoring. These interventions are complementary, not alternatives to DAT. The danger of waiting for confirmation or organ failure During an outbreak, there can be a tendency to wait for laboratory confirmation before initiating treatment, or to regard severe disease only after organ complications become obvious. Both approaches risk missing the opportunity for earlier intervention. Current clinical guidance supports prompt treatment of suspected respiratory diphtheria when DAT is indicated, without unnecessarily delaying management while awaiting laboratory confirmation. Laboratory testing remains essential for surveillance and public health response, but clinical management must be driven by the patient’s presentation and the available evidence. Similarly, clinicians should actively look for warning signs—including progressive respiratory difficulty, extensive pseudomembrane formation, neck swelling, dysphagia, voice changes, cardiac abnormalities, neurological symptoms and reduced urine output—before organ failure is established. DAT is one part of comprehensive case management A severe diphtheria case requires a coordinated approach. DAT addresses circulating toxin; appropriate antibiotics eradicate C. diphtheriae and prevent further toxin production. Airway assessment, cardiac and neurological monitoring, renal assessment, infection prevention and control, and organ-specific supportive care address the consequences and risks of severe disease. From an outbreak-response perspective, the quality of care therefore cannot be judged simply by whether DAT was administered. We should also ask: Was it given promptly? Were antibiotics started? Was the airway assessed? Were cardiac and neurological complications actively monitored? Was renal dysfunction recognised early? Was the patient escalated to an appropriate level of care? These questions shift the focus from a single intervention to the performance of the entire case-management pathway. A lesson from the field My experience in sub-national diphtheria case management in Nigeria has reinforced a simple principle: the effectiveness of an outbreak response depends on the speed and quality of the whole clinical pathway. DAT is important, but it is not a rescue treatment for established organ failure. The practical message is straightforward: recognise suspected diphtheria early, administer DAT promptly when clinically indicated, start appropriate antibiotics, protect the airway, monitor for cardiac and neurological complications, identify organ dysfunction early, provide appropriate supportive care and escalate patients when necessary. The earlier diphtheria is recognised and treated, the greater the opportunity to limit further toxin-mediated injury. DAT is not magic. Its value lies in doing what it is designed to do—neutralising circulating toxin—while clinicians simultaneously do everything necessary to manage the injury that has already occurred. References 1. World Health Organization. Clinical management of diphtheria: guideline. Geneva: World Health Organization; 2024. WHO/DIPH/Clinical/2024.1. doi/identifier: WHO-DIPH-Clinical-2024.1. 2. Centers for Disease Control and Prevention. Clinical Guidance for Diphtheria. Atlanta, GA: CDC; updated July 31, 2026. 3. Centers for Disease Control and Prevention. Diphtheria Antitoxin. Atlanta, GA: CDC; updated July 31, 2026. 4. Centers for Disease Control and Prevention. Diphtheria Symptoms and Complications. Atlanta, GA: CDC; updated July 31, 2026.